1. Home
  2. KOS vs AKBA Comparison

KOS vs AKBA Comparison

Compare KOS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$2.34

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.27

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
AKBA
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
729.1M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
KOS
AKBA
Price
$2.34
$1.27
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$1.76
$5.75
AVG Volume (30 Days)
17.6M
3.4M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
$1,288,352,000.00
N/A
Revenue This Year
$17.57
$17.63
Revenue Next Year
$8.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$1.14
52 Week High
$2.55
$4.08

Technical Indicators

Market Signals
Indicator
KOS
AKBA
Relative Strength Index (RSI) 69.21 43.52
Support Level $1.52 $1.14
Resistance Level $2.43 $1.57
Average True Range (ATR) 0.20 0.11
MACD 0.05 0.01
Stochastic Oscillator 80.29 26.09

Price Performance

Historical Comparison
KOS
AKBA

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: